Mariner
VKTX icon

Mariner’s Viking Therapeutics VKTX Stock Holding History

Mariner’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,806
Closed -$285K – 3705
2025
Q1 		$285K Sell
11,806
-2,620
-18% -$82.8K ﹤0.01% 2674
2024
Q4 		$580K Buy
14,426
+4,161
+41% +$237K ﹤0.01% 2064
2024
Q3 		$644K Buy
10,265
+755
+8% +$44.3K ﹤0.01% 1933
2024
Q2 		$504K Buy
9,510
+1,052
+12% +$69K ﹤0.01% 2042
2024
Q1 		$694K Buy
+8,458
New +$376K ﹤0.01% 1783

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Mariner's VKTX Position: Q2 2025 in Review

Mariner sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 11,806 shares — an estimated $285K sold.

Mariner first reported a position in VKTX in Q1 2024 and held it in 5 quarters. The position peaked at $694K in Q1 2024. 392 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Mariner reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 11,806 Viking Therapeutics shares in Q2 2025, an estimated $285K.
  • Mariner first reported a position in Viking Therapeutics in Q1 2024 and held it in 5 quarters.
  • Mariner's Viking Therapeutics position peaked at $694K in Q1 2024.
  • 392 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.